MAPT and Alzheimer disease: The limited efficacy of anti-amyloid monoclonal antibodies in AD suggests that additional mechanisms related to abnormal tau processing [65], mitochondrial dysfunction [66], synaptic degeneration [67], and neuroinflammation [15] should be further explored to fully understand the pathogenesis of AD.